AroCell Q2 2022: Good cost control, somewhat lower sales
Research Update
2022-08-18
08:00
Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.
OB
Oscar Bergman
Disclosures and disclaimers